Switching to biosimilar infliximab: real world data in patients with severe inflammatory arthritis
Switching to biosimilar infliximab: real world data in patients with severe inflammatory arthritis
Objective: to describe real world experience of switching from originator TNF inhibitor Remicade (infliximab), to the biosimilar Inflectra (infliximab) in severe inflammatory arthritis.
Methods: from May 2015 patients receiving Remicade (infliximab) were switched to Inflectra (infliximab). We compared discontinuation rates due to inefficacy and adverse events (AEs) after switching to Inflectra (infliximab) with discontinuation rates whilst receiving Remicade (infliximab) in the year prior to the switch.
Results: 59 patients agreed to switch, with 51 (86%) continuing after a mean follow-up 362 days (12.1 months.)
Conclusion: safety and clinical efficacy of Inflectra (infliximab) appears similar to that of Remicade (infliximab).
Holroyd, Christopher
bd50c028-34f5-493c-86da-eeb5f7ea9e78
Parker, L.M.
a6341bf2-0ec9-4ec2-9517-d6238a6eb83d
Bennett, S.
8b90d240-340a-4235-9592-0f34c58cd499
Zarroug, J.
88edb601-cdb3-4584-90bd-8dce720ee422
Underhill, C.
5c1589aa-1607-481a-ac82-fbc5b2ede255
Davidson, B.
1a3f15c8-5e74-4551-9d18-6c41448b65af
Armstrong, Ray
496b7c78-3799-4913-a570-7f80e4464c1a
Harvey, Nicholas
ce487fb4-d360-4aac-9d17-9466d6cba145
Dennison, Elaine
ee647287-edb4-4392-8361-e59fd505b1d1
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
Edwards, C. J.
97e65c42-4286-4ce4-b354-010169b72143
Holroyd, Christopher
bd50c028-34f5-493c-86da-eeb5f7ea9e78
Parker, L.M.
a6341bf2-0ec9-4ec2-9517-d6238a6eb83d
Bennett, S.
8b90d240-340a-4235-9592-0f34c58cd499
Zarroug, J.
88edb601-cdb3-4584-90bd-8dce720ee422
Underhill, C.
5c1589aa-1607-481a-ac82-fbc5b2ede255
Davidson, B.
1a3f15c8-5e74-4551-9d18-6c41448b65af
Armstrong, Ray
496b7c78-3799-4913-a570-7f80e4464c1a
Harvey, Nicholas
ce487fb4-d360-4aac-9d17-9466d6cba145
Dennison, Elaine
ee647287-edb4-4392-8361-e59fd505b1d1
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
Edwards, C. J.
97e65c42-4286-4ce4-b354-010169b72143
Holroyd, Christopher, Parker, L.M., Bennett, S., Zarroug, J., Underhill, C., Davidson, B., Armstrong, Ray, Harvey, Nicholas, Dennison, Elaine, Cooper, Cyrus and Edwards, C. J.
(2018)
Switching to biosimilar infliximab: real world data in patients with severe inflammatory arthritis.
Clinical and Experimental Rheumatology.
Abstract
Objective: to describe real world experience of switching from originator TNF inhibitor Remicade (infliximab), to the biosimilar Inflectra (infliximab) in severe inflammatory arthritis.
Methods: from May 2015 patients receiving Remicade (infliximab) were switched to Inflectra (infliximab). We compared discontinuation rates due to inefficacy and adverse events (AEs) after switching to Inflectra (infliximab) with discontinuation rates whilst receiving Remicade (infliximab) in the year prior to the switch.
Results: 59 patients agreed to switch, with 51 (86%) continuing after a mean follow-up 362 days (12.1 months.)
Conclusion: safety and clinical efficacy of Inflectra (infliximab) appears similar to that of Remicade (infliximab).
Text
Switching to biosimilar infliximab- Journal of Rheumatology 2nd submission
- Accepted Manuscript
More information
Accepted/In Press date: 1 December 2017
e-pub ahead of print date: 15 January 2018
Identifiers
Local EPrints ID: 417508
URI: http://eprints.soton.ac.uk/id/eprint/417508
ISSN: 0392-856X
PURE UUID: 1d12e52a-4373-444d-9dbc-a282bd817325
Catalogue record
Date deposited: 01 Feb 2018 17:30
Last modified: 19 Jul 2022 04:02
Export record
Contributors
Author:
Christopher Holroyd
Author:
L.M. Parker
Author:
S. Bennett
Author:
J. Zarroug
Author:
C. Underhill
Author:
B. Davidson
Author:
Ray Armstrong
Author:
C. J. Edwards
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
